CAMBRIDGE, Mass. (August 8, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the 37th Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2017 at 2:30 PM Eastern Time at the InterContinental Boston in Boston, MA. This is the first time that the company has been invited to present at this conference. Mr. Perrin’s presentation will feature recent updates to the company’s Neuro-Spinal Scaffold™ program.
A live webcast will be available at http://wsw.com/webcast/canaccord26/nviv and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in 5-10 minutes before the event to ensure a timely connection.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.